BeiGene Ltd-ADR

BeiGene Ltd is a global biopharmaceutical company with its headquarters in Beijing, China. The firm has offices in Cambridge Massachusetts and around the United States, as well as in Switzerland and across China. It has an expansive global clinical development program, with patients in 34 countries across five continents participating in a range of clinical trials. Founded in 2010, the firm employs over 5,000 people, with a clinical team of more than 1,600 professionals. BeiGene is engaged in the development and commercialisation of innovative molecularly-targeted and immune-oncology drugs for the treatment of various cancers. The firm is publicly traded on the NASDAQ GS where it is listed under the stock ticker BGNE. In January 2021, the BGNE price chart showed a 52-week high of $376.45 and a 52-week low of $118.55, with a market cap of $34.15bn. The company was originally founded as a small research and development company in China. In 2016, it became the first Chinese biotechnology firm to go public on the NASDAQ with an initial public offering worth $182m. A dual primary listing on the Hong Kong Stock Exchange in 2018 resulted in an IPO of $902m. Are you thinking of diversifying your investments on eToro? Start today by adding BGNE stock to your portfolio.